Vertex Grows Gene Editing Presence:Biopharma Acquires Exonics Therapeutics and Expands CRISPR Therapeutics Collaboration

摘要

Vertex Pharmaceuticals will carry out a potentially $2 billion expansion of its presence in gene editing through a pair of deals intended to enable the company to develop novel treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy typel (DM1).Vertex announced plans to acquire Exonics Therapeutics forapproximately $1 billion, as well as to spend an additional up-to $1,175 billion to expand a 31/2-year-old, potentially $2.5-billion-plus collaboration with CRISPR Therapeutics that has resulted in the first clinical trial of a gene editing therapy candidate sponsored by U.S. companies.